LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

Home・Aandelen Lijst・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

63.97 1.64

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

61.05

Max

65.12

Belangrijke statistieken
By Trading Economics
Inkomsten	52M 28M
Verkoop	7.6M 264M
K/W Sectorgemiddelde	39.463 108.767
EPS	0.22
Winstmarge	10.696
Werknemers	711
EBITDA	206M 57M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+29.6% upside

Dividenden
By Dow Jones
Volgende Winsten	11 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-1.4B 8.8B
Vorige openingsprijs	62.33
Vorige sluitingsprijs	63.97

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

11.5 / 12.23 Steun & Weerstand

Arrowhead Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 mrt 2026, 23:41 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2 mrt 2026, 23:37 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2 mrt 2026, 23:26 UTC

Belangrijke Nieuwsgebeurtenissen

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2 mrt 2026, 22:41 UTC

Marktinformatie

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2 mrt 2026, 22:32 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

2 mrt 2026, 22:32 UTC

Marktinformatie

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2 mrt 2026, 22:21 UTC

Marktinformatie

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2 mrt 2026, 22:11 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 mrt 2026, 22:11 UTC

Marktinformatie

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2 mrt 2026, 22:10 UTC

Acquisities, Fusies, Overnames

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2 mrt 2026, 22:06 UTC

Marktinformatie

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2 mrt 2026, 22:00 UTC

Marktinformatie

Winsten

Global Forex and Fixed Income Roundup: Market Talk

2 mrt 2026, 22:00 UTC

Marktinformatie

Winsten

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2 mrt 2026, 21:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Energy & Utilities Roundup: Market Talk

2 mrt 2026, 21:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

2 mrt 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

2 mrt 2026, 21:35 UTC

Acquisities, Fusies, Overnames

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2 mrt 2026, 21:34 UTC

Acquisities, Fusies, Overnames

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2 mrt 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2 mrt 2026, 21:17 UTC

Belangrijke Nieuwsgebeurtenissen

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2 mrt 2026, 20:44 UTC

Winsten

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2 mrt 2026, 20:43 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2 mrt 2026, 20:28 UTC

Winsten

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2 mrt 2026, 20:25 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2 mrt 2026, 20:24 UTC

Winsten

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2 mrt 2026, 20:14 UTC

Acquisities, Fusies, Overnames

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2 mrt 2026, 20:12 UTC

Belangrijke Nieuwsgebeurtenissen

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2 mrt 2026, 20:08 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Forex and Fixed Income Roundup: Market Talk

2 mrt 2026, 20:08 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2 mrt 2026, 20:05 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Peer Vergelijking

Prijswijziging

Arrowhead Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

29.6% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 82 USD 29.6%

Hoogste 110 USD

Laagste 35 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Arrowhead Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Arrowhead Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

11.5 / 12.23Steun & Weerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.